TD Cowen Issues Positive Forecast for Abbott Laboratories (NYSE:ABT) Stock Price

Key Points

• TD Cowen raised Abbott Laboratories’ price target to $135 from $115 and maintained a “buy” rating, implying 16.26% upside from the prior close. Analysts overall hold a “Moderate Buy” consensus with an average target of $119.50.
• Abbott exceeded quarterly expectations with $1.31 in EPS and $12.59 billion in revenue, while revenue grew 13% year over year. The company guided for full-year 2026 EPS of $5.45–$5.60.
• New product momentum, including FDA authorization for the Libre Duo glucose-and-ketone monitor, supports Abbott’s continuous glucose-monitoring business, though the company faces mixed diagnostics trends and a $670 million settlement related to infant-formula litigation.

Abbott Laboratories (NYSE:ABT - Get Free Report) had its target price raised by research analysts at TD Cowen from $115.00 to $135.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the healthcare product maker's stock. TD Cowen's target price would indicate a potential upside of 16.26% from the stock's previous close.

Other equities analysts have also issued research reports about the company. UBS Group lowered their price objective on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. BTIG Research increased their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a report on Friday, July 17th. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a research note on Wednesday, May 27th. Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. Finally, Piper Sandler reiterated an "overweight" rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $119.50.

Abbott Laboratories Stock Performance

ABT stock traded down $0.55 during midday trading on Tuesday, reaching $116.12. 7,502,958 shares of the company were exchanged, compared to its average volume of 11,820,817. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The firm has a market capitalization of $200.94 billion, a price-to-earnings ratio of 37.58, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59. The business has a 50-day moving average price of $100.64 and a two-hundred day moving average price of $100.03. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. During the same quarter last year, the company posted $1.26 EPS. Abbott Laboratories's quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Institutional Investors Weigh In On Abbott Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in ABT. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories during the fourth quarter worth $25,000. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories during the 4th quarter worth $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories during the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories in the 4th quarter worth about $26,000. Finally, Abound Financial LLC bought a new position in Abbott Laboratories in the fourth quarter valued at about $26,000. 75.18% of the stock is owned by institutional investors.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first wearable device designed to continuously monitor both glucose and ketone levels. The system may help detect rising ketones associated with diabetic ketoacidosis, expands Abbott’s FreeStyle Libre ecosystem and is designed to work with automated insulin-delivery systems. The approval strengthens Abbott’s competitive position in the continuous glucose-monitoring market and could create a new growth opportunity. FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients
• Positive Sentiment: Analyst comparisons with DexCom characterize Abbott as having more attractive valuation and price-target upside, while both companies pursue growth through CGM adoption and product innovation. Abbott also benefits from the launch of Medtronic’s MiniMed Flex pump using an Abbott-made sensor, which could support sensor demand and broaden ecosystem exposure. Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?
• Neutral Sentiment: Abbott’s diagnostics business shows healthy routine testing demand and 13% growth in cancer diagnostics, but weaker respiratory testing is offsetting part of that momentum. This creates a mixed near-term outlook for the segment. Here's What Is Shaping Abbott's Diagnostics Growth
• Neutral Sentiment: Recent institutional activity was mixed: Golden Reserve Retirement LLC increased its Abbott position substantially, while Choreo LLC reduced its holdings modestly. These changes are relatively small and unlikely to materially affect the stock.
• Negative Sentiment: Abbott agreed to pay approximately $670 million to settle claims involving about 2,000 premature infants whose families alleged its specialized formulas contributed to necrotizing enterocolitis. Although the settlement removes uncertainty surrounding a major verdict and does not admit liability, it highlights continuing litigation exposure and imposes a significant financial charge. Abbott Pays $670 Million to Settle Formula Claims as Legal Risks Persist

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source